An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Gemini Therapeutics to Participate in Upcoming Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Gemini Therapeutics (Nasdaq: GMTX) has announced that CEO Jason Meyeburg will participate in upcoming investor conferences this November. He is scheduled to speak at the Stifel 2021 Virtual Healthcare Conference on November 15 at 8:40 AM ET and the Jefferies London Healthcare Conference on November 18, available on-demand from 8 AM GMT. The company's lead product, GEM103, targets age-related macular degeneration and is currently in clinical trials. Webcasts of these events will be archived for 30 days on Gemini's website.
Positive
None.
Negative
None.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the following investor conferences in November:
Stifel 2021 Virtual Healthcare Conference Date: Monday, November 15, 2021 Time: 8:40 AM ET
Jefferies London Healthcare Conference Date: Thursday, November 18, 2021 The presentation will be available on-demand starting at 8 AM GMT on Thursday, November 18, 2021.
The webcasts of the events will be available on the "Events & Presentations" page on the Company's website. A replay of the webcasts will be archived on the Company's website for 30 days following the presentations.
About Gemini Therapeutics
Gemini Therapeutics is a clinical stage precision medicine company developing novel therapeutic compounds to treat genetically defined age-related macular degeneration (AMD). Gemini’s lead candidate, GEM103, is a recombinant form of human complement factor H protein (CFH) and is designed to address both complement hyperactivity and restore retinal health in patients with AMD. GEM103 is currently in a Phase 2a trial in dry AMD patients with a CFH risk variant and a Phase 1/2a study in patients with neovascular age-related macular degeneration with or at risk for macular atrophy. Gemini is also working to advance a potentiating antibody for CFH, GEM307, towards clinical development for treatment of systemic diseases.
Availability of Other Information About Gemini Therapeutics
Investors and others should note that we communicate with our investors and the public using our website (www.geminitherapeutics.com), the investor relations website (https://investors.geminitherapeutics.com/), and on social media (Twitter and LinkedIn), including but not limited to investor presentations and investor fact sheets, U.S. Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that Gemini posts on these channels and websites could be deemed to be material information. As a result, Gemini encourages investors, the media, and others interested in Gemini to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on Gemini’s investor relations website and may include additional social media channels. The contents of Gemini’s website or these channels, or any other website that may be accessed from its website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended.
When will Gemini Therapeutics participate in investor conferences?
Gemini Therapeutics will participate in the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies London Healthcare Conference on November 18, 2021.
What time is the presentation at the Stifel Conference for GMTX?
The presentation at the Stifel 2021 Virtual Healthcare Conference is scheduled for 8:40 AM ET on November 15, 2021.
Where can I find the webcasts for Gemini Therapeutics' investor presentations?
The webcasts will be available on the 'Events & Presentations' page of Gemini Therapeutics' website and archived for 30 days.
What is GEM103 developed by Gemini Therapeutics?
GEM103 is a recombinant form of human complement factor H protein aimed at treating genetically defined age-related macular degeneration.
What other products is Gemini Therapeutics working on?
Gemini is also advancing GEM307, an antibody for complement factor H, targeting systemic diseases.
